Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
77.80
+0.10 (+0.13%)
4:15:20 PM EDT: $77.88 +0.08 (+0.10%)
Other Pre-Announcement

Merck Announces First-Quarter 2021 Financial Results

Published: 04/29/2021 11:41 GMT
Merck & Co Inc (MRK) - Merck Announces First-quarter 2021 Financial Results.
Sees FY Non-GAAP Earnings per Share $6.48 to $6.68 Including Items.
Sees FY GAAP Earnings per Share $5.05 to $5.25.
Q1 Non-GAAP Earnings per Share $1.40.
Q1 GAAP Earnings per Share $1.25.
Full-year 2021 Sales Estimated to Be Between $51.8 Billion and $53.8 Billion.
Qtrly Keytruda Sales $3,899 Million Versus $3,284 Million.
Qtrly Januvia/janumet $1,295 Million Versus $1,277 Million.
Qtrly Gardasil/gardasil 9 Sales $917 Million Versus $1,097 Million.
Assuming Completion of Organon Spinoff, Co Sees 2021 Revenue From Continuing Operations to Be Between $45.8 Billion and $47.8 Billion.
First-quarter 2021 Sales Were $12.1 Billion, In-line With First-quarter 2020.
Q1 Earnings per Share View $1.63, Revenue View $12.66 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2021 Earnings per Share View $6.56, Revenue View $52.48 Billion -- Refinitiv Ibes Data (analyst estimates).
Expects That Organon Spinoff Will Occur on June 2, 2021.
Continues to Experience Strong Global Underlying Demand Across Its Business.
Merck & Co - With Respect to Covid-19 Pandemic, Estimated Negative Impact to Merck’s First Quarter Pharmaceutical Revenue Was Approximately $600 Million.
Estimates Pandemic Will Have Net Unfavorable Impact to 2021 Revenues of About 3%, All of Which Relates to Pharmaceutical Segment.
For Full-year 2021, Merck Expects Pandemic to Have a Negligible Impact on Operating Expenses.
Expects the Spinoff of Organon to Be Completed on June 2, 2021.